Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaccarani, M.en
dc.contributor.authorDeininger, M.en
dc.contributor.authorRosti, G.en
dc.contributor.authorHochhaus, A.en
dc.contributor.authorSoverini, S.en
dc.contributor.authorApperley, J.en
dc.contributor.authorCervantes, F.en
dc.contributor.authorClark, R.en
dc.contributor.authorCortes, J.en
dc.contributor.authorGuilhot, F.en
dc.contributor.authorHansen-Hjorth, H.en
dc.contributor.authorHughes, T.en
dc.contributor.authorKantarjian, H.en
dc.contributor.authorKim, D.en
dc.contributor.authorLarson, R.en
dc.contributor.authorLipton, J.en
dc.contributor.authorMahon, F.en
dc.contributor.authorMartinelli, G.en
dc.contributor.authorMayer, J.en
dc.contributor.authorMuller, M.en
dc.contributor.authoret al.en
dc.identifier.citationBlood, 2013; 122(6):872-884en
dc.description.abstractAdvances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels ≤10% at 3 months, <1% at 6 months, and ≤0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph+] >95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.en
dc.description.statementofresponsibilityMichele Baccarani, Michael W. Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jorge E. Cortes, François Guilhot, Henrik Hjorth-Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong-Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles Schiffer, Richard Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, and Rüdiger Hehlmannen
dc.publisherAmer Soc Hematologyen
dc.rights© 2013 by The American Society of Hematologyen
dc.subjectHumans; Benzamides; Piperazines; Pyrimidines; Thiazoles; Fusion Proteins, bcr-abl; Antineoplastic Agents; Prognosis; Treatment Outcome; Stem Cell Transplantation; Europe; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Randomized Controlled Trials as Topic; Imatinib Mesylate; Dasatiniben
dc.titleEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013en
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.